Nationwide Fund Advisors’s Juno Therapeutics, Inc. JUNO Stock Holding History

Nationwide Fund Advisors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-7,500	Closed	-$141K	–	3230
2016 Q4	$141K	Hold	7,500	–	–	﹤0.01%	2757
2016 Q3	$225K	Buy	+7,500	New	+$233K	﹤0.01%	2574
2015 Q2	–	Sell	-4,280	Closed	-$260K	–	3394
2015 Q1	$260K	Buy	4,280 +150	+4%	+$7.28K	﹤0.01%	2566
2014 Q4	$216K	Buy	+4,130	New	+$185K	﹤0.01%	2595

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BCM

Biomark Capital Management Greenwich, Connecticut $8.9M AUM 97.06% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Nationwide Fund Advisors's JUNO Position: Q1 2017 in Review

Nationwide Fund Advisors sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2017, closing a stake of 7,500 shares — an estimated $141K sold.

Nationwide Fund Advisors first reported a position in JUNO in Q4 2014 and held it in 4 quarters. The position peaked at $260K in Q1 2015. 157 funds tracked by Wall St. Rank hold JUNO as of Q1 2017.

Nationwide Fund Advisors reported no remaining Juno Therapeutics, Inc. position as of Q1 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 7,500 Juno Therapeutics, Inc. shares in Q1 2017, an estimated $141K.
Nationwide Fund Advisors first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 4 quarters.
Nationwide Fund Advisors's Juno Therapeutics, Inc. position peaked at $260K in Q1 2015.
157 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2017.

Based on Nationwide Fund Advisors's 13F filing for Q1 2017, filed 21 Apr 2017.